Please replace the Sequence Listing at pp. 39-59 of the specification with the enclosed amended Sequence Listing and renumber the pages of the specification accordingly.

## IN THE CLAIMS

Please cancel original Claims 1-27 and 30-36.

Please add new Claims 37, 38, and 39, as indicated below in clean form pursuant to 37 C.F.R. § 1.121(c)(1)(i). A marked up version of the new claims is attached pursuant to 37 C.F.R. § 1.121(c)(1)(ii) (Tab A), and a complete set of claims 28, 29, and 37-39 of this divisional application is attached pursuant to 37 C.F.R. § 1.121(c)(3) (Tab B).

## Newly Added Claims in Clean Form Pursuant to 37 C.F.R. § 1.121(c)(1)(i)

- 37. (new) The method according to claim 28, wherein the B cell epitope portion of the vaccine peptide comprises a carboxyl terminal region of human CETP consisting of between 6 and 26 consecutive amino acids of SEQ ID NO:1.
- 38. (new) The method according to claim 37, wherein the vaccine peptide comprises the amino acid sequence of SEQ ID NO:2.
- 39. (new) The method according to claim 37, wherein the vaccine peptide comprises a dimer of the amino acid sequence of SEQ ID NO:2.